Beyond RECIST 1.1: The AI Endpoint Playbook for Modern Oncology Trials
DDDr. Dereck Mush, MD, MBA
Sep 18
Altis Labs
AI imaging endpoints designed to predict survival outcomes earlier in oncology clinical trials.
What they do
Altis Labs develops computational imaging models for oncology drug development. Its IPRO platform uses routine radiology scans to estimate survival outcomes and treatment effect, giving trial sponsors an additional way to assess therapies before conventional endpoints mature.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Clinical trial endpoints
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Toronto, Canada
- Region
- North America
- Founded
- 2019
- Total funding
- $25M raised
Notable investors: OrbiMed, Qiming Venture Partners USA, Innovation Endeavors, Lumira Ventures.
Also in Pharma & Drug Discovery
Related on The Signal
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
DDDr. Dereck Mush, MD, MBA
Jun 5
Decentralized and adaptive trial designs move from pilot to default in biotech development plans
DDDr. Dereck Mush, MD, MBA
Apr 29
Decentralized Clinical Trials Promised Faster Recruitment. The Evidence on Actual Performance Is In.
DDDr. Dereck Mush, MD, MBA
Jun 27